Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

ClinicalTrials.gov ID: NCT01667679

Public ClinicalTrials.gov record NCT01667679. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Study identification

NCT ID
NCT01667679
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Avanir Pharmaceuticals
Industry
Enrollment
275 participants

Conditions and interventions

Interventions

  • 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally Drug
  • OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2012
Primary completion
Feb 28, 2014
Completion
May 31, 2014
Last update posted
Apr 11, 2017

2012 – 2014

United States locations

U.S. sites
13
U.S. states
10
U.S. cities
13
Facility City State ZIP Site status
San Francisco Clinical Research Center San Francisco California 94109
California Medical Clinic for Headache Santa Monica California 90404
Associated Neurologists of Southern CT, P.C. Fairfied Connecticut 06824
Premiere Research Institute West Palm Beach Florida 33407
MedVadis Watertown Massachusetts 02472
Michigan Head and Pain Institute Ann Arbor Michigan 48104-5199
ClinVest Springfield Missouri 65807
Mercy Health Research St Louis Missouri 63141
DENT Neurologic Institute Amherst New York 14226
Headache Welness Center Greensboro North Carolina 27405
PMG Research of Winston Salem, LLC Winston-Salem North Carolina 27103
Jefferson Headache Center Philadelphia Pennsylvania 19107
Coastal Carolina Research Center Mt. Pleasant South Carolina 29464

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01667679, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 11, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01667679 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →